Study of Sensory Attenuation in Functional Movement Disorders
1 other identifier
observational
70
1 country
1
Brief Summary
Functional movement disorders (FMD) are conditions where people experience unusual movements or difficulties with walking, not caused by a specific brain or nerve injury but related to how the brain controls movements. Functional movement disorders are common in clinical practice and can lead to significant disability and healthcare costs. A key feature of FMD is a problem with self-agency-the feeling that we are in control of our own movements. Many patients with FMD feel that their abnormal movements happen without their control. Sensory attenuation is closely linked to self-agency. It's the brain's way of reducing the intensity of sensations caused by our own movements. For example, you can't tickle yourself because your brain knows it's your own action. In people with FMD, this process doesn't work properly. As a result, they might feel their movements are involuntary. Previous research shows that sensory attenuation is reduced in FMD, but the studies so far have been small. This study will investigate sensory attenuation in a larger group of FMD patients and compare it with healthy individuals. The goal is to see if reduced sensory attenuation could be used as a marker to measure the severity of FMD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 2, 2025
CompletedFirst Posted
Study publicly available on registry
March 12, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
March 12, 2025
March 1, 2025
3 years
March 2, 2025
March 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sensory attenuation measurement
The primary outcome of this study is to measure sensory attenuation in patients with functional movement disorders (FMD) using the force-matching paradigm. Sensory attenuation will be quantified by calculating the ratio of matched forces to target forces in both self and external conditions.
Day 1
Secondary Outcomes (1)
Correlation between WHODAS2 and PMDS with sensory attenuation.
Day 1
Study Arms (2)
Cases
Functional Movement Disorder
Controls
Healthy subjects
Eligibility Criteria
movement disorder clinic
You may qualify if:
- (1) Diagnosed with a functional movement disorder (2) Age \>18 years
You may not qualify if:
- (1) Moderate to severe action tremor in the dominant hand that interferes with the tasks. (2) Upper limb peripheral neuropathy. (3) Inability to read or understand English.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital
London, Ontario, N6A5A5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professot
Study Record Dates
First Submitted
March 2, 2025
First Posted
March 12, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
September 1, 2028
Study Completion (Estimated)
December 1, 2028
Last Updated
March 12, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share
At this time, IPD will not be shared due to confidentiality concerns.